Evidence map›Paper›PMID 40738478›Full record

ReviewKidney international2025

Management recommendations for kidney transplantation in patients with plasma cell dyscrasia.

Naoka Murakami, Christopher D Blosser, Allison B Webber, Gaurav Gupta, Neeraj Singh, Samhita Boppana, Samip Master, Raviprasenna Parasuraman, Erica L Campagnaro, Anuja Java and 15 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Naoka MurakamiDivision of Nephrology, Washington University in St. Louis, Saint Louis, Missouri, USA. Electronic address: naoka@wustl.edu.
Christopher D BlosserDivision of Nephrology, University of Washington, Seattle, Washington, USA; Fred Hutch Cancer Center, Seattle, Washington, USA.
Allison B WebberDivision of Nephrology, University of California San Francisco, San Francisco, California, USA.
Gaurav GuptaDivision of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA.
Neeraj SinghDivision of Nephrology, Willis Knighton Medical Center, Shreveport, Louisiana, USA.
Samhita BoppanaDivision of Nephrology, Willis Knighton Medical Center, Shreveport, Louisiana, USA.
Samip MasterDivision of Hematology Oncology, Willis Knighton Medical Center, Shreveport, Louisiana, USA.
Raviprasenna ParasuramanDivision of Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
Erica L CampagnaroDivision of Hematology, University of Michigan, Ann Arbor, Michigan, USA.
Anuja JavaDivision of Nephrology, Washington University in St. Louis, Saint Louis, Missouri, USA.
Ben SprangersDepartment of Immunology and Infection, Biomedical Research Institute, UHasselt, Diepenbeek, Belgium; Department of Nephrology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Bhavna Bhasin-ChhabraDivision of Nephrology, Mayo Clinic, Phoenix, Arizona, USA.
Erik LumDivision of Nephrology, University of California Los Angeles, Los Angeles, California, USA.
Diala KhirfanDivision of Nephrology, Tulane University, New Orleans, Louisiana, USA.
Mariam P AlexanderDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Miklos Z MolnarDivision of Nephrology and Hypertension, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA.
Brian BenesDivision of Nephrology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Ajay Kumar ThakurDivision of Nephrology, The Ohio State University, Columbus, Ohio, USA.
Naresh BummaDivision of Hematology, The Ohio State University, Columbus, Ohio, USA.
Sabine KaramDivision of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA; Division of Nephrology and Hypertension, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Frank BridouxCentre de Référence de l'Amylose AL et des autres Maladies par Dépôts d'Immunoglobuline Monoclonale, Department of Nephrology, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France.
Vaishali SanchorawalaAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Nelson LeungDivision of Nephrology, Mayo Clinic, Rochester, Minnesota, USA.
Heather LandauMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic address: LandauH@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Patients with plasma cell dyscrasia, including multiple myeloma, AL amyloidosis, and monoclonal gammopathy of renal significance, face a high burden of end-stage kidney disease, which limits survival and quality of life. Although kidney transplant offers potential benefits, it remains underused because of the high risk of recurrence and historically poor outcomes. A multidisciplinary panel of transplant nephrologists, hematologists/oncologists, and pathologists convened to evaluate contemporary evidence and evolving strategies in kidney transplant for plasma cell dyscrasias and end-stage kidney disease. Advances in plasma cell dyscrasia therapies are improving survival and expanding kidney transplant eligibility. However, key challenges remain, including optimizing hematologic response pre-kidney transplant and managing immunosuppression to mitigate recurrence and avoid infection complications. Ongoing research and multidisciplinary collaboration are essential to refine transplant selection, integrate biomarkers for risk stratification, and develop tailored post-kidney transplant surveillance. These efforts may increase access to kidney transplant and improve outcomes for patients with plasma cell dyscrasia and end-stage kidney disease.

Indexed as

Kidney Failure, ChronicKidney TransplantationParaproteinemiasHumansImmunosuppressive AgentsPatient SelectionRecurrenceRisk AssessmentRisk FactorsTreatment OutcomeImmunosuppressive AgentsAL amyloidosiskidney transplantmonoclonal gammopathymultiple myelomaplasma cell dyscrasia

Identifiers

PMID40738478
PMCPMC13521042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.